CWS Financial Advisors LLC Has $92.95 Million Stock Holdings in Stryker Co. (NYSE:SYK)

CWS Financial Advisors LLC lifted its position in Stryker Co. (NYSE:SYK) by 0.2% during the third quarter, Holdings Channel reports. The institutional investor owned 257,294 shares of the medical technology company’s stock after buying an additional 505 shares during the quarter. Stryker makes up approximately 32.9% of CWS Financial Advisors LLC’s investment portfolio, making the stock its largest position. CWS Financial Advisors LLC’s holdings in Stryker were worth $92,950,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Wealth Enhancement Advisory Services LLC lifted its position in shares of Stryker by 78.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock valued at $45,260,000 after acquiring an additional 58,673 shares during the last quarter. OFI Invest Asset Management lifted its holdings in shares of Stryker by 3,210.9% during the second quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company’s stock valued at $1,062,000 after purchasing an additional 3,243 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Stryker by 2.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company’s stock worth $210,289,000 after purchasing an additional 16,504 shares in the last quarter. Sivik Global Healthcare LLC increased its stake in Stryker by 8.0% in the 3rd quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock worth $9,754,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Fiera Capital Corp raised its holdings in Stryker by 42.1% during the 2nd quarter. Fiera Capital Corp now owns 16,713 shares of the medical technology company’s stock worth $5,687,000 after buying an additional 4,948 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SYK. BTIG Research boosted their price target on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. StockNews.com cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Evercore ISI raised their target price on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Citigroup lifted their price target on Stryker from $406.00 to $411.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, UBS Group increased their price objective on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $393.65.

Insider Buying and Selling at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 2,121 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $370.00, for a total transaction of $784,770.00. Following the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,715,540. This trade represents a 17.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 66,781 shares of company stock worth $24,612,275. 5.90% of the stock is currently owned by corporate insiders.

Stryker Stock Performance

NYSE SYK opened at $388.14 on Friday. Stryker Co. has a 1-year low of $285.79 and a 1-year high of $398.20. The company has a 50 day moving average of $367.97 and a 200-day moving average of $350.94. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The firm has a market cap of $147.97 billion, a price-to-earnings ratio of 41.60, a PEG ratio of 2.93 and a beta of 0.91.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the firm posted $2.46 EPS. On average, equities analysts forecast that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.